Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above
40000 patients around the world
Available in Argentina, Chile, Mexico
This is a global phase III clinical trial to evaluate efficacy,safety, immuogenicity of
Ad5-nCoV manufactured by Cansino and Beijing Institute of Biotechnology in health adults aged
18 years old and above.
The study will be double-blind, placebo-controlled trial with participants randomly allocated
1:1 to placebo and experimental vaccine cohorts.
The immunization schedule is one doses intramuscular injections (deltoid).